Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Arrowhead Pharmaceuticals Inc shares valued at $493,412 were sold by Ferrari Mauro on Nov 28 ’25. At $56.39 per share, Ferrari Mauro sold 8,750 shares. The insider’s holdings dropped to 68,764 shares worth approximately $4.45 million following the completion of this transaction.
Also, Mauro Ferrari purchased 8,750 shares, netting a total of over 493,062 in proceeds.
Before that, Hamilton James C had sold 20,000 shares from its account. In a trade valued at $700,000, the Chief Medical Officer traded Arrowhead Pharmaceuticals Inc shares for $35.00 each. Upon closing the transaction, the insider’s holdings decreased to 20,000 shares, worth approximately $13.72 million.
As published in their initiating research note from Goldman on June 05, 2024, Arrowhead Pharmaceuticals Inc [ARWR] has been a Neutral and the price target has been revised to $31. Analysts at BofA Securities started covering the stock with ‘”a Buy”‘ outlook in a report released in early December. As of September 19, 2023, Citigroup has initiated its “Neutral” rating for ARWR. Earlier on July 21, 2023, TD Cowen initiated its rating. Their recommendation was “an Outperform” for ARWR stock.
Analyzing ARWR Stock Performance
On last trading session, Arrowhead Pharmaceuticals Inc [NASDAQ: ARWR] plunged -0.64% to $64.66. The stock’s lowest price that day was $64.19, but it reached a high of $67.14 in the same session. During the last five days, there has been a surge of approximately 12.04%. Over the course of the year, Arrowhead Pharmaceuticals Inc shares have jumped approximately 145.48%. Shares of the company reached a 52-week high of $67.14 on 12/04/25 and a 52-week low of $9.57 on 04/07/25.
Support And Resistance Levels for Arrowhead Pharmaceuticals Inc (ARWR)
According to the 24-hour chart, there is a support level at 63.52, which, if violated, would cause prices to drop to 62.38. In the upper region, resistance lies at 66.47. The next price resistance is at 68.28. RSI (Relative Strength Index) is 77.75 on the 14-day chart, showing overbought technical sentiment.
Is Arrowhead Pharmaceuticals Inc subject to short interest?
Stocks of Arrowhead Pharmaceuticals Inc saw a sharp steep in short interest on 2025-11-14 dropping by 52323.0 shares to 11.6 million. Data from Yahoo Finance shows that the short interest on 2025-10-15 was 11.65 million shares. A decline of -0.45% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 6.92 of the overall float, the days-to-cover ratio (short ratio) decline to 6.92.
Which companies own the most shares of Arrowhead Pharmaceuticals Inc (ARWR)?
In terms of Arrowhead Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 66.5 in the next 12 months, up nearly 2.2% from the previous closing price of $65.07. Analysts anticipate Arrowhead Pharmaceuticals Inc stock to reach 85 by 2025, with the lowest price target being 48. In spite of this, 9 analysts ranked Arrowhead Pharmaceuticals Inc stock as Buy at the end of 2025. On May 12, 2023, SVB Securities assigned a price target of “a Market perform” to the stock and downgraded coverage with a $40.
